Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes

Objectives: The prognostic significance of the progesterone receptor (PR) has been widely investigated in luminal A and luminal B [human epidermal growth factor receptor 2 (HER2)–] breast cancer subtypes, both of which are estrogen receptor (ER)-positive and HER2-negative. In contrast, few studies h...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Toshiaki Utsumi, Naomi Kobayashi, Masahiro Hikichi, Kaori Ushimado, Makoto Kuroda
Formato:	article
Lenguaje:	EN
Publicado:	Fujita Medical Society 2021
Materias:	breast cancer progesterone receptor (pr) human epidermal growth factor receptor 2 (her2) luminal b subtype Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/96109edb93504573b01a0e8c7eb32a00
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:96109edb93504573b01a0e8c7eb32a00
record_format	dspace
spelling	oai:doaj.org-article:96109edb93504573b01a0e8c7eb32a002021-11-10T04:35:38ZNegative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes10.20407/fmj.2020-0232189-72472189-7255https://doaj.org/article/96109edb93504573b01a0e8c7eb32a002021-11-01T00:00:00Zhttps://www.jstage.jst.go.jp/article/fmj/7/4/7_2020-023/_pdf/-char/enhttps://doaj.org/toc/2189-7247https://doaj.org/toc/2189-7255Objectives: The prognostic significance of the progesterone receptor (PR) has been widely investigated in luminal A and luminal B [human epidermal growth factor receptor 2 (HER2)–] breast cancer subtypes, both of which are estrogen receptor (ER)-positive and HER2-negative. In contrast, few studies have focused on PR status in luminal B (HER2+) tumors. The aim of this study was to evaluate the impact of positive PR status on outcomes in patients with luminal B (HER2–) or luminal B (HER2+) breast cancer. Methods: Survival analysis was performed to estimate the likelihood of distant recurrence and death in 469 breast cancer patients with the luminal B (HER2–) or luminal B (HER2+) subtype. The relationship between PR and HER2 status was also assessed. Results: Of 387 luminal B (HER2–) and 82 luminal B (HER2+) cancers, PR+ was significantly more frequent in the former than the latter (86.3% vs. 61.0%, respectively; P<0.001). In univariate analysis, PR was identified as a significant favorable prognostic factor for distant disease–free survival and overall survival in both subtypes, but in multivariate analysis PR was not an independent prognostic factor. Conclusions: After patients with luminal B subtype were divided into two subgroups according to HER2 status, there was evidence of a relatively good prognosis in the PR+ subgroup. Further studies with a larger number of patients are recommended to validate these findings.Toshiaki UtsumiNaomi KobayashiMasahiro HikichiKaori UshimadoMakoto KurodaFujita Medical Societyarticlebreast cancerprogesterone receptor (pr)human epidermal growth factor receptor 2 (her2)luminal b subtypeMedicine (General)R5-920ENFujita Medical Journal, Vol 7, Iss 4, Pp 130-135 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer progesterone receptor (pr) human epidermal growth factor receptor 2 (her2) luminal b subtype Medicine (General) R5-920
spellingShingle	breast cancer progesterone receptor (pr) human epidermal growth factor receptor 2 (her2) luminal b subtype Medicine (General) R5-920 Toshiaki Utsumi Naomi Kobayashi Masahiro Hikichi Kaori Ushimado Makoto Kuroda Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes
description	Objectives: The prognostic significance of the progesterone receptor (PR) has been widely investigated in luminal A and luminal B [human epidermal growth factor receptor 2 (HER2)–] breast cancer subtypes, both of which are estrogen receptor (ER)-positive and HER2-negative. In contrast, few studies have focused on PR status in luminal B (HER2+) tumors. The aim of this study was to evaluate the impact of positive PR status on outcomes in patients with luminal B (HER2–) or luminal B (HER2+) breast cancer. Methods: Survival analysis was performed to estimate the likelihood of distant recurrence and death in 469 breast cancer patients with the luminal B (HER2–) or luminal B (HER2+) subtype. The relationship between PR and HER2 status was also assessed. Results: Of 387 luminal B (HER2–) and 82 luminal B (HER2+) cancers, PR+ was significantly more frequent in the former than the latter (86.3% vs. 61.0%, respectively; P<0.001). In univariate analysis, PR was identified as a significant favorable prognostic factor for distant disease–free survival and overall survival in both subtypes, but in multivariate analysis PR was not an independent prognostic factor. Conclusions: After patients with luminal B subtype were divided into two subgroups according to HER2 status, there was evidence of a relatively good prognosis in the PR+ subgroup. Further studies with a larger number of patients are recommended to validate these findings.
format	article
author	Toshiaki Utsumi Naomi Kobayashi Masahiro Hikichi Kaori Ushimado Makoto Kuroda
author_facet	Toshiaki Utsumi Naomi Kobayashi Masahiro Hikichi Kaori Ushimado Makoto Kuroda
author_sort	Toshiaki Utsumi
title	Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes
title_short	Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes
title_full	Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes
title_fullStr	Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes
title_full_unstemmed	Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes
title_sort	negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal b her2-positive and -negative subtypes
publisher	Fujita Medical Society
publishDate	2021
url	https://doaj.org/article/96109edb93504573b01a0e8c7eb32a00
work_keys_str_mv	AT toshiakiutsumi negativeprogesteronereceptorstatuscorrelateswithincreasedriskofbreastcancerrecurrenceinluminalbher2positiveandnegativesubtypes AT naomikobayashi negativeprogesteronereceptorstatuscorrelateswithincreasedriskofbreastcancerrecurrenceinluminalbher2positiveandnegativesubtypes AT masahirohikichi negativeprogesteronereceptorstatuscorrelateswithincreasedriskofbreastcancerrecurrenceinluminalbher2positiveandnegativesubtypes AT kaoriushimado negativeprogesteronereceptorstatuscorrelateswithincreasedriskofbreastcancerrecurrenceinluminalbher2positiveandnegativesubtypes AT makotokuroda negativeprogesteronereceptorstatuscorrelateswithincreasedriskofbreastcancerrecurrenceinluminalbher2positiveandnegativesubtypes
_version_	1718440579427205120

Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes

Ejemplares similares